183 related articles for article (PubMed ID: 26079809)
1. Increased occurrence of mutant rtI233V of HBV in patients receiving adefovir therapy.
Liu Y; Xin S; Ye X; Chen R; Xu Z; Li X; Ye H; Cheng S; Xu D
Antivir Ther; 2016; 21(1):9-16. PubMed ID: 26079809
[TBL] [Abstract][Full Text] [Related]
2. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
Liu Y; Liu W; Li X; Xu Z; Wang X; Li C; Chen L; Xin S; Xu D
Antivir Ther; 2014; 19(6):551-8. PubMed ID: 24710668
[TBL] [Abstract][Full Text] [Related]
3. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil.
Liu Y; Li X; Xin S; Xu Z; Chen R; Yang J; Liu L; Wong VW; Yang D; Chan HL; Xu D
J Viral Hepat; 2015 Mar; 22(3):328-34. PubMed ID: 25132017
[TBL] [Abstract][Full Text] [Related]
4. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
Qi X; Xiong S; Yang H; Miller M; Delaney WE
Antivir Ther; 2007; 12(3):355-62. PubMed ID: 17591025
[TBL] [Abstract][Full Text] [Related]
6. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).
Osiowy C; Villeneuve JP; Heathcote EJ; Giles E; Borlang J
J Clin Microbiol; 2006 Jun; 44(6):1994-7. PubMed ID: 16757589
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
[TBL] [Abstract][Full Text] [Related]
8. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
10. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
[TBL] [Abstract][Full Text] [Related]
11. Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
Cho YK; Cui XJ; Jeong SU; Song BC
Antiviral Res; 2014 Dec; 112():8-17. PubMed ID: 25303802
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
Svarovskaia ES; Curtis M; Zhu Y; Borroto-Esoda K; Miller MD; Berg T; Lavocat F; Zoulim F; Kitrinos KM
J Viral Hepat; 2013 Feb; 20(2):131-40. PubMed ID: 23301548
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B.
Zhong Y; Lv J; Li J; Xing X; Zhu H; Su H; Chen L; Zhou X
Antiviral Res; 2012 Jan; 93(1):185-90. PubMed ID: 22138714
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
[TBL] [Abstract][Full Text] [Related]
15. HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D.
Liu Y; Miller MD; Kitrinos KM
Liver Int; 2014 Aug; 34(7):1025-32. PubMed ID: 24118725
[TBL] [Abstract][Full Text] [Related]
16. rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B.
Liu LJ; Wang JH; Du SC; Tian JH; Yang RF; Wei L
J Viral Hepat; 2010 Mar; 17 Suppl 1():66-72. PubMed ID: 20586936
[TBL] [Abstract][Full Text] [Related]
17. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
Suzuki F; Kumada H; Nakamura H
J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
Amini-Bavil-Olyaee S; Herbers U; Mohebbi SR; Sabahi F; Zali MR; Luedde T; Trautwein C; Tacke F
J Hepatol; 2009 Oct; 51(4):647-54. PubMed ID: 19586679
[TBL] [Abstract][Full Text] [Related]
19. [Dissection of mechanism for the adefovir dipivoxil resistance in chronic hepatitis B patients].
Zeng AZ; Lu P; Deng H; Cai SF; Yang C; Xin XJ; Guo JJ; Li QL; Deng XH; Huang AL
Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):730-4. PubMed ID: 19874686
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir.
Curtis M; Zhu Y; Borroto-Esoda K
J Infect Dis; 2007 Nov; 196(10):1483-6. PubMed ID: 18008227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
